Palivizumab is a monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) disease in high‑risk infants and young children. Administered by injection, it binds RSV, reducing hospitalization risk. It is a specialized biomedical term often encountered in clinical literature and medical discussions, not part of everyday vocabulary.
Full pronunciation guide
